Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Inkeun | - |
dc.contributor.author | Choi, Seung Joon | - |
dc.contributor.author | Kim, Young Saing | - |
dc.contributor.author | Ahn, Hee Kyung | - |
dc.contributor.author | Hong, Junshik | - |
dc.contributor.author | Sym, Sun Jin | - |
dc.contributor.author | Park, Jinny | - |
dc.contributor.author | Cho, Eun Kyung | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Shin, Yong Ju | - |
dc.contributor.author | Shin, Dong Bok | - |
dc.date.available | 2020-02-28T00:42:55Z | - |
dc.date.created | 2020-02-07 | - |
dc.date.issued | 2016-10 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/7832 | - |
dc.description.abstract | Purpose The aim of this study was to verify prognostic factors including sarcopenia in patients with recurrent or metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. Materials and Methods Medical records and computed tomography scan of consecutive patients treated with palliative gemcitabine-based chemotherapy from 2008 to 2014 were reviewed. The lumbar skeletal muscle index at third lumbar spine level was computed, and together with clinico-laboratory factors, univariate and multivariable analyses for overall survival (OS) were performed. Results A total of 88 patients were found. Median age was 65 years, and male patients were predominant (67.0%). Most patients had initially metastatic disease (72.7%), and gemcitabine monotherapy was administered in 29 patients (33.0%) while gemcitabine plus erlotinib was administered in 59 patients (67.0%). Seventy-six patients (86.3%) had sarcopenia. With a median follow-up period of 44.3 months (range, 0.6 to 44.3 months), median OS was 5.35 months (95% confidence interval [CI], 4.11to 6.59). In univariate and multivariable analysis, high carcinoembryonic antigen level (hazard ratio [HR], 4.18; 95% CI, 1.95 to 8.97; p < 0.001), initially metastatic diease (HR, 3.37; 95% CI, 1.55 to 7.32; p=0.002), sarcopenia (HR, 2.97; 95% CI, 1.20 to 7.86; p=0.019), neutrophilia (HR, 2.94; 95% CI, 1.27 to 6.79; p=0.012), and high lactate dehydrogenase level (HR, 1.96; 95% CI, 1.07 to 3.58; p=0.029) were identified as independent prognostic factors for OS. Conclusion Five independent prognostic factors in patients with recurrent or metastatic pancreatic cancer who received gemcitabine-based chemotherapy were identified. These findings may be helpful in prediction of prognosis in clinical practice and can be used as a stratification factor for clinical trials. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.subject | BODY-MASS INDEX | - |
dc.subject | CANCER-PATIENTS | - |
dc.subject | PREDICT SURVIVAL | - |
dc.subject | PLUS GEMCITABINE | - |
dc.subject | SARCOPENIA | - |
dc.subject | MUSCLE | - |
dc.subject | PREVALENCE | - |
dc.subject | STATISTICS | - |
dc.subject | FOLFIRINOX | - |
dc.subject | BOOTSTRAP | - |
dc.title | Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000385212800011 | - |
dc.identifier.doi | 10.4143/crt.2015.250 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, v.48, no.4, pp.1264 - 1273 | - |
dc.identifier.kciid | ART002154642 | - |
dc.identifier.scopusid | 2-s2.0-84996879697 | - |
dc.citation.endPage | 1273 | - |
dc.citation.startPage | 1264 | - |
dc.citation.title | CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 48 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Park, Inkeun | - |
dc.contributor.affiliatedAuthor | Choi, Seung Joon | - |
dc.contributor.affiliatedAuthor | Kim, Young Saing | - |
dc.contributor.affiliatedAuthor | Ahn, Hee Kyung | - |
dc.contributor.affiliatedAuthor | Hong, Junshik | - |
dc.contributor.affiliatedAuthor | Sym, Sun Jin | - |
dc.contributor.affiliatedAuthor | Park, Jinny | - |
dc.contributor.affiliatedAuthor | Cho, Eun Kyung | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.contributor.affiliatedAuthor | Shin, Yong Ju | - |
dc.contributor.affiliatedAuthor | Shin, Dong Bok | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Pancreatic neoplasms | - |
dc.subject.keywordAuthor | Gemcitabine | - |
dc.subject.keywordAuthor | Drug therapy | - |
dc.subject.keywordAuthor | Sarcopenia | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordPlus | BODY-MASS INDEX | - |
dc.subject.keywordPlus | CANCER-PATIENTS | - |
dc.subject.keywordPlus | PREDICT SURVIVAL | - |
dc.subject.keywordPlus | PLUS GEMCITABINE | - |
dc.subject.keywordPlus | SARCOPENIA | - |
dc.subject.keywordPlus | MUSCLE | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | STATISTICS | - |
dc.subject.keywordPlus | FOLFIRINOX | - |
dc.subject.keywordPlus | BOOTSTRAP | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.